A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
A phase 2 trial of Durvalumab, Bevacizumab in hepatocellular carcinoma, run by AstraZeneca, active and no longer recruiting.
Overview
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE is a phase 2 interventional study registered as NCT06040099 by AstraZeneca, with 58 participants enrolled, started 2024-02-13 and due to reach its primary completion in 2026-07-01. Interventions recorded: Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE). Conditions listed: Hepatocellular Carcinoma (HCC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialTheraSphere With Durvalumab and Tremelimumab for HCC
Shares Durvalumab, Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma, Yttrium-90.
- CompanySirtex Medical
Shares Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma, Yttrium-90.
- IndicationIntermediate hepatocellular carcinoma (BCLC B)
Shares Durvalumab, Hepatocellular carcinoma, Yttrium-90.
- CompanyBoston Scientific
Shares Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma, Yttrium-90.
- TermTARE / SIRT (radioembolisation with yttrium-90)
Shares Hepatocellular carcinoma, Yttrium-90.
- TrialSARAH and SIRveNIB
Shares Hepatocellular carcinoma, Yttrium-90.
- IsotopeHolmium-166
Shares Hepatocellular carcinoma, Yttrium-90.
- AgentHolmium-166 microspheres
Shares Hepatocellular carcinoma, Yttrium-90.